Skip to main content
. 2022 Aug 19;11(16):4874. doi: 10.3390/jcm11164874

Figure 2.

Figure 2

The survival time of hepatocellular carcinoma patients receiving different tyrosine kinase inhibitors and immune checkpoint inhibitors. (LEN, lenvatinib; NIVO, nivolumab; OS, overall survival; PEMBRO, pembrolizumab; PFS, progression free survival; SOR, sorafenib).